Royal Bank of Canada Has $424,000 Stake in GW Pharmaceuticals PLC (GWPH)

Royal Bank of Canada lifted its stake in shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) by 0.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,240 shares of the biopharmaceutical company’s stock after acquiring an additional 18 shares during the quarter. Royal Bank of Canada’s holdings in GW Pharmaceuticals PLC were worth $424,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently modified their holdings of GWPH. Ameriprise Financial Inc. bought a new position in shares of GW Pharmaceuticals PLC during the first quarter worth about $230,000. Parametric Portfolio Associates LLC raised its position in shares of GW Pharmaceuticals PLC by 21.4% during the first quarter. Parametric Portfolio Associates LLC now owns 5,132 shares of the biopharmaceutical company’s stock worth $621,000 after acquiring an additional 903 shares during the last quarter. Geode Capital Management LLC raised its position in shares of GW Pharmaceuticals PLC by 39.5% during the first quarter. Geode Capital Management LLC now owns 11,893 shares of the biopharmaceutical company’s stock worth $1,438,000 after acquiring an additional 3,368 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of GW Pharmaceuticals PLC during the first quarter worth about $10,909,000. Finally, HighTower Advisors LLC raised its position in shares of GW Pharmaceuticals PLC by 10.3% during the first quarter. HighTower Advisors LLC now owns 2,044 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 191 shares during the last quarter. Institutional investors own 75.71% of the company’s stock.

A number of equities analysts have recently issued reports on the company. Goldman Sachs Group, Inc. (The) restated a “neutral” rating and set a $124.00 price objective on shares of GW Pharmaceuticals PLC in a research report on Friday, October 6th. Zacks Investment Research downgraded GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Maxim Group set a $135.00 price objective on GW Pharmaceuticals PLC and gave the stock a “buy” rating in a research report on Monday, August 7th. Cantor Fitzgerald set a $208.00 price objective on GW Pharmaceuticals PLC and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Finally, Evercore ISI began coverage on GW Pharmaceuticals PLC in a research note on Wednesday, August 16th. They set an “outperform” rating and a $154.00 target price for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $144.55.

Shares of GW Pharmaceuticals PLC (NASDAQ:GWPH) opened at $111.95 on Wednesday. GW Pharmaceuticals PLC has a one year low of $92.65 and a one year high of $136.95. The company has a debt-to-equity ratio of 0.02, a current ratio of 10.39 and a quick ratio of 10.26.

TRADEMARK VIOLATION WARNING: This piece of content was posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://transcriptdaily.com/2017/11/15/royal-bank-of-canada-has-424000-stake-in-gw-pharmaceuticals-plc-gwph.html.

GW Pharmaceuticals PLC Company Profile

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Institutional Ownership by Quarter for GW Pharmaceuticals PLC (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply